Global menu

Our global pages

Close

Eversheds Sutherland has advised Senzime

  • Sweden

    01-06-2022

    Eversheds Sutherland has advised Senzime AB (publ), listed on Nasdaq Stockholm, in connection with the entering into of an agreement to acquire 100 percent of the shares in the Boston-based US company Respiratory Motion, Inc. for an initial consideration of USD 19 million on a cash- and debt-free basis with an additional potential earn-out payment of up to USD 25 million. The total consideration is payable in Senzime shares and/or cash.

    Through the acquisition, Senzime expands its product portfolio within the market for monitoring of vital signs and extends its capability to capture a larger share of the patient journey outside of the operating room as well.

    Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery.

    For complete information, please see https://senzime.com/us/mfn_news/senzime-has-entered-into-an-agreement-to-acquire-the-us-company-respiratory-motion/.   
      
    Eversheds Sutherland's team mainly consisted of Jens André and Anna Thoms (Stockholm) and Lance Phillips and Evan Johnson (Chicago).    

    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back